1. Scrip
  2. >>Focus On Asia

Emerging Markets Earnings Roundup: Sanofi Channel Stuffing In Brazil? (Part 4)

 
• By Vikas Dandekar

Sanofi CEO Chris Viehbacher showed clear signs of disappointment during the company’s earnings call, admitting emerging markets under-performed, and revealing a debacle in Brazil that appears to be channel stuffing.

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on Asia and emerging markets. For previous emerging markets Q2 coverage, see ([A#28130716008]) and ([A#28130717012]). For Part 3, please see ([A#28130730008]).

Sanofi’s second quarter earnings jolted analysts. The French drug maker turned lower than expected performance, marked by the fallout of unexpected risks in emerging markets, particularly Brazil and China....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list